Mode
Text Size
Log in / Sign up

Automated insulin delivery increases time-in-range by 9.88% in young children with type 1 diabetesAutomated insulin delivery improves blood sugar for young children

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that AID systems significantly improve time-in-range by 9.88% in children under 7 with type 1 diabetes.

This meta-analysis synthesizes data from randomized controlled trials, single-arm studies, and cohort studies to evaluate the efficacy of automated insulin delivery (AID) systems in young children under 7 years old with type 1 diabetes. The analysis focused on primary outcomes including time-in-range (TIR), as well as secondary metrics such as hyperglycemia exposure and glycated hemoglobin.

The meta-analysis reported a significant increase in TIR by 9.88% (equivalent to 2.37 hours/day; 95% CI 9.14 to 10.62, P <.0001). Specifically, daytime TIR improved by 6.88% and overnight TIR showed a more substantial improvement of 16.85%. While glycated hemoglobin showed modest reductions, specific effect sizes for this metric were not reported.

Safety data indicated that AID systems have good safety profiles in this pediatric population. There were no significant changes in hypoglycemia exposure, and severe hypoglycemia and diabetic ketoacidosis occurred infrequently. The authors conclude that AID systems provide greater benefits for improving glycemic outcomes in young children with type 1 diabetes. These findings are reported with moderate certainty.

How this fits prior evidence

This meta-analysis extends previous evidence regarding automated insulin delivery (AID) systems in pediatric populations. It builds upon the finding that AID systems increase time-in-range by 9.29% in children with Type 1 Diabetes without increasing hypoglycemia risk. This current analysis provides a more specific look at the younger cohort (under 7 years), confirming significant improvements in both daytime and overnight TIR while maintaining a favorable safety profile.

Managing Type 1 diabetes is a constant challenge for families with very young children. Keeping blood sugar levels steady enough to stay healthy requires constant attention. New research looking at data from over 1,000 children under age seven shows that automated insulin delivery systems can help make this daily task more manageable.

The study found that these automated systems helped children spend about 2.37 more hours each day in a healthy blood range. This improvement was even more noticeable during the night, where kids spent significantly more time with stable levels. The data also showed modest improvements in glycated hemoglobin, which is a common way doctors track long-term blood sugar control.

Safety remains a top priority for parents and doctors. The study reported that these systems had good safety profiles for young children. While some cases of severe low blood sugar or ketoacidosis occurred, they were infrequent. These findings suggest that automated tools can provide more consistent results while maintaining a solid safety profile for the youngest patients.

What this means for you:
Automated insulin delivery helps children under 7 stay in healthy blood sugar ranges longer and improves overnight stability.

Common questions

How does automated insulin delivery help young children?

These systems help children under the age of 7 spend more time in a healthy blood sugar range. Specifically, the data showed an increase of about 2.37 hours per day. This improvement was especially noticeable at night, where children spent significantly more time with stable levels.

Is it safe for children under 7 to use these systems?

The study found that these systems have good safety profiles for young children. While some cases of severe low blood sugar or ketoacidosis were reported, they were infrequent. The data did not show significant changes in the amount of time children spent with low blood sugar.

Does it work better during the day or at night?

While both daytime and overnight levels improved, the improvement was much larger at night. Children using these systems saw a 16.85% increase in time spent in a healthy range during the night compared to a 6.88% increase during the day.

Study Details

Study typeMeta analysis
EvidenceLevel 1
Follow-up84.0 mo
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: Automated insulin delivery (AID) in young children (<7 years) with type 1 diabetes has not yet been systematically evaluated. MATERIALS AND METHODS: Web of Science, PubMed, Scopus, CENTRAL, and ClinicalTrials.gov were searched from inception to December 9, 2025. Studies reporting glycemic outcomes in children younger than 7 years were included in this meta-analysis. Studies not published in English were excluded. The primary outcome was the change in time-in-range (TIR; 70-180 mg/dL). Pooled estimates were calculated using random-effects models and expressed as mean changes (MCs) with 95% confidence intervals (CIs). RESULTS: This study included 30 studies (9 randomized controlled trials, 7 single-arm studies, and 14 cohort studies) involving 1155 young children. AID systems were associated with a significant increase in TIR (MC, 9.88% [95% CI 9.14 to 10.62], I2 = 8%, P < .0001, moderate certainty), equivalent to 2.37 hours/day. Favorable improvement was also observed during the daytime (MC, 6.88% [95% CI 5.70 to 8.07]) and overnight (MC, 16.85% [95% CI 13.48 to 20.22]). TIR improvements were comparable across devices: MiniMed 670G (9.65%), MiniMed 780G (10.04%), CamAPS FX (10.58%), Control-IQ (9.51%), Omnipod 5 (10.25%), and Open Source (6.77%). AID use was also associated with reduced hyperglycemia exposure and modest reductions in glycated hemoglobin, without significant changes in hypoglycemia exposure. Episodes of severe hypoglycemia and diabetic ketoacidosis were infrequent. CONCLUSION: This systematic review with meta-analysis revealed that AID systems have greater benefits for improving glycemic outcomes and have good safety profiles in young children with type 1 diabetes.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.